Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 1.03
ELGX's Cash to Debt is ranked lower than
55% of the 183 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.42 vs. ELGX: 1.03 )
Ranked among companies with meaningful Cash to Debt only.
ELGX' s 10-Year Cash to Debt Range
Min: 1.03   Max: No Debt
Current: 1.03

Equity to Asset 0.48
ELGX's Equity to Asset is ranked lower than
66% of the 174 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.59 vs. ELGX: 0.48 )
Ranked among companies with meaningful Equity to Asset only.
ELGX' s 10-Year Equity to Asset Range
Min: 0.41   Max: 0.96
Current: 0.48

0.41
0.96
F-Score: 3
Z-Score: 4.48
M-Score: -2.39
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) -22.18
ELGX's Operating margin (%) is ranked lower than
78% of the 181 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.85 vs. ELGX: -22.18 )
Ranked among companies with meaningful Operating margin (%) only.
ELGX' s 10-Year Operating margin (%) Range
Min: -237.33   Max: -4.47
Current: -22.18

-237.33
-4.47
Net-margin (%) -32.40
ELGX's Net-margin (%) is ranked lower than
81% of the 181 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.03 vs. ELGX: -32.40 )
Ranked among companies with meaningful Net-margin (%) only.
ELGX' s 10-Year Net-margin (%) Range
Min: -228.8   Max: 15.84
Current: -32.4

-228.8
15.84
ROE (%) -38.90
ELGX's ROE (%) is ranked lower than
82% of the 175 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.27 vs. ELGX: -38.90 )
Ranked among companies with meaningful ROE (%) only.
ELGX' s 10-Year ROE (%) Range
Min: -56.88   Max: 15.58
Current: -38.9

-56.88
15.58
ROA (%) -19.36
ELGX's ROA (%) is ranked lower than
79% of the 185 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.87 vs. ELGX: -19.36 )
Ranked among companies with meaningful ROA (%) only.
ELGX' s 10-Year ROA (%) Range
Min: -50.63   Max: 11.48
Current: -19.36

-50.63
11.48
ROC (Joel Greenblatt) (%) -72.34
ELGX's ROC (Joel Greenblatt) (%) is ranked lower than
80% of the 182 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 9.74 vs. ELGX: -72.34 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
ELGX' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -1382.35   Max: -22.12
Current: -72.34

-1382.35
-22.12
Revenue Growth (3Y)(%) 15.40
ELGX's Revenue Growth (3Y)(%) is ranked higher than
88% of the 145 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.70 vs. ELGX: 15.40 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
ELGX' s 10-Year Revenue Growth (3Y)(%) Range
Min: -41.8   Max: 66.8
Current: 15.4

-41.8
66.8
EBITDA Growth (3Y)(%) -7.80
ELGX's EBITDA Growth (3Y)(%) is ranked lower than
78% of the 119 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 6.70 vs. ELGX: -7.80 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
ELGX' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -50   Max: 73.8
Current: -7.8

-50
73.8
EPS Growth (3Y)(%) -0.70
ELGX's EPS Growth (3Y)(%) is ranked lower than
61% of the 119 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 6.20 vs. ELGX: -0.70 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
ELGX' s 10-Year EPS Growth (3Y)(%) Range
Min: -51.6   Max: 128.9
Current: -0.7

-51.6
128.9
» ELGX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2014

ELGX Guru Trades in Q2 2014

Pioneer Investments 585,991 sh (+2.54%)
Paul Tudor Jones Sold Out
» More
Q3 2014

ELGX Guru Trades in Q3 2014

Steven Cohen 216,452 sh (New)
Pioneer Investments 738,560 sh (unchged)
» More
Q4 2014

ELGX Guru Trades in Q4 2014

Steven Cohen Sold Out
Pioneer Investments 689,134 sh (-6.69%)
» More
Q1 2015

ELGX Guru Trades in Q1 2015

Jim Simons 81,400 sh (New)
Pioneer Investments 598,774 sh (-13.11%)
» More
» Details

Insider Trades

Latest Guru Trades with ELGX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Guru Investment Theses on Endologix Inc

Meridian Funds Comments on Endologix Inc - Dec 17, 2014

Endologix (ELGX) is a medical device company with products that treat aortic abdominal aneurisms (AAA). Recently the company experienced a decline in sales growth after the conclusion of a clinical trial rollout. We believed the revenue issue was temporary and were very excited about a new product called Nellix that has the potential to more than double Endologix’s market share in AAA procedures. During the quarter, share performance disappointed after the company disclosed that sales would again miss expectations, this time due to an intensifying competitive environment. While management outlined an aggressive response, including product enhancements intended to further improve upon the lowest complication rate in the AAA industry, we have reduced our position until we can gain greater clarity on how effective these efforts will be in the market.

From Meridian Funds (Trades, Portfolio)’ Meridian Contrarian Fund 3Q 2014 Commentary.

Check out Meridian Funds latest stock trades

Top Ranked Articles about Endologix Inc

Meridian Funds Comments on Endologix Inc
Endologix (ELGX) is a medical device company with products that treat aortic abdominal aneurisms (AAA). Recently the company experienced a decline in sales growth after the conclusion of a clinical trial rollout. We believed the revenue issue was temporary and were very excited about a new product called Nellix that has the potential to more than double Endologix’s market share in AAA procedures. During the quarter, share performance disappointed after the company disclosed that sales would again miss expectations, this time due to an intensifying competitive environment. While management outlined an aggressive response, including product enhancements intended to further improve upon the lowest complication rate in the AAA industry, we have reduced our position until we can gain greater clarity on how effective these efforts will be in the market. Read more...

Ratios

vs
industry
vs
history
P/B 9.30
ELGX's P/B is ranked lower than
122% of the 164 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.00 vs. ELGX: 9.30 )
Ranked among companies with meaningful P/B only.
ELGX' s 10-Year P/B Range
Min: 1.69   Max: 14.14
Current: 9.3

1.69
14.14
P/S 7.10
ELGX's P/S is ranked lower than
134% of the 154 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.75 vs. ELGX: 7.10 )
Ranked among companies with meaningful P/S only.
ELGX' s 10-Year P/S Range
Min: 1.14   Max: 53.43
Current: 7.1

1.14
53.43
Current Ratio 5.04
ELGX's Current Ratio is ranked higher than
81% of the 178 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.55 vs. ELGX: 5.04 )
Ranked among companies with meaningful Current Ratio only.
ELGX' s 10-Year Current Ratio Range
Min: 2.15   Max: 20.25
Current: 5.04

2.15
20.25
Quick Ratio 3.76
ELGX's Quick Ratio is ranked higher than
78% of the 178 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.62 vs. ELGX: 3.76 )
Ranked among companies with meaningful Quick Ratio only.
ELGX' s 10-Year Quick Ratio Range
Min: 2   Max: 19.04
Current: 3.76

2
19.04
Days Inventory 251.46
ELGX's Days Inventory is ranked lower than
87% of the 175 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 121.06 vs. ELGX: 251.46 )
Ranked among companies with meaningful Days Inventory only.
ELGX' s 10-Year Days Inventory Range
Min: 120.76   Max: 1408.32
Current: 251.46

120.76
1408.32
Days Sales Outstanding 64.47
ELGX's Days Sales Outstanding is ranked lower than
57% of the 156 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 61.58 vs. ELGX: 64.47 )
Ranked among companies with meaningful Days Sales Outstanding only.
ELGX' s 10-Year Days Sales Outstanding Range
Min: 6.64   Max: 125.56
Current: 64.47

6.64
125.56

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 25.30
ELGX's Price/Tangible Book is ranked lower than
130% of the 149 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.20 vs. ELGX: 25.30 )
Ranked among companies with meaningful Price/Tangible Book only.
ELGX' s 10-Year Price/Tangible Book Range
Min: 0.81   Max: 114.8
Current: 25.3

0.81
114.8
Price/Median PS Value 1.00
ELGX's Price/Median PS Value is ranked higher than
68% of the 157 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.00 vs. ELGX: 1.00 )
Ranked among companies with meaningful Price/Median PS Value only.
ELGX' s 10-Year Price/Median PS Value Range
Min: 0.18   Max: 6.65
Current: 1

0.18
6.65
Earnings Yield (Greenblatt) -3.00
ELGX's Earnings Yield (Greenblatt) is ranked lower than
76% of the 178 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.90 vs. ELGX: -3.00 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) only.
ELGX' s 10-Year Earnings Yield (Greenblatt) Range
Min: -3.3   Max: 0
Current: -3

-3.3
0

Business Description

Industry: Medical Instruments & Equipment » Medical Instruments & Supplies
Compare:WST, BAX, COV, TMO, COO » details
Traded in other countries:RM1.Germany,
Endologix Inc was incorporated in California on March 16, 1992 under the name Cardiovascular Dynamics, Inc. and reincorporated in Delaware in June 1993. The Company develops, manufactures, markets and sells medical devices for the treatment of abdominal aortic aneurysms (AAA). Its main products are intended for the treatment of AAA through minimally-invasive endovascular repair (EVAR) or endovascular sealing ('EVAS'), solution for sealing the aneurysm sac while maintaining blood flow through two blood flow lumens. Once AAA develops, it continues to enlarge and, if left untreated, becomes increasingly susceptible to rupture. The Company's EVAR products consist of: a cobalt chromium alloy stent covered by polytetrafluoroethylene graft material; and an accompanying delivery system. The Company's EVAS product consists of: bilateral covered stents with endobags; a biocompatible polymer injected into the endobags to seal the aneurysm; and a delivery system and polymer dispenser. All of its products are manufactured, assembled, and packaged at its 60,000 square foot leased facilities in Irvine, California and markets and sells its products in the U.S. and in 11 Western European countries through a direct sales force and network of agents. The Company sells EVAR products through exclusive independent distributors or agents in 14 other European countries, Japan, 9 countries in South America, New Zealand and Mexico. Its main competitors include: Medtronic, Inc., W.L. Gore Inc., and Cook Medical Products, Inc., and new market entrants, TrvVascular, Inc. and Lombard Medical Technologies. The Company is subject to additional licensing and regulatory requirements relating to safe working conditions, manufacturing practices, environmental protection, fire hazard control, and disposal of hazardous or potentially hazardous substances.
» More Articles for ELGX

Headlines

Articles On GuruFocus.com
Meridian Funds Comments on Endologix Inc Dec 17 2014 
Meridian Contrarian Fund 3Q 2014 Commentary Dec 17 2014 
Weekly CFO Sells Highlight: ELGX, LOW, NWS, SBUX, WLP Dec 18 2012 
Endologix Inc Reports Operating Results (10-K) Mar 16 2011 
Endologix Inc Reports Operating Results (10-Q) Nov 08 2010 
Weekly CFO Buys Highlight: FCTOA, GNBT, CTTC, ELGX, ARTC Nov 06 2010 
Endologix Inc Reports Operating Results (10-Q) Jul 30 2010 
Weekly CEO Sells Highlight: Cisco Systems Inc, AmerisourceBergen Corp, PAETEC HOLDING CORP, Endologi May 22 2010 
Endologix Inc (ELGX) CEO John D Mcdermott sells 225,000 Shares May 17 2010 
Endologix Inc Reports Operating Results (10-Q) May 10 2010 

More From Other Websites
Endologix to Present at the Jefferies 2015 Global Healthcare Conference May 27 2015
ENDOLOGIX INC /DE/ Files SEC form 8-K, Regulation FD Disclosure May 27 2015
ENDOLOGIX INC /DE/ Financials May 06 2015
Endologix Reports 10% Revenue Growth for the First Quarter 2015 May 04 2015
Endologix to Participate in Two Investor Conferences in May May 04 2015
10-Q for Endologix, Inc. May 01 2015
ENDOLOGIX INC /DE/ Files SEC form 8-K, Change in Directors or Principal Officers Apr 30 2015
Endologix reports 1Q loss Apr 29 2015
Endologix reports 1Q loss Apr 29 2015
Endologix Inc Earnings Call scheduled for 5:00 pm ET today Apr 29 2015
Positive Nellix Clinical Data From the EVAS FORWARD Global Registry Presented at the 37th Annual... Apr 29 2015
Endologix Appoints Leslie Norwalk to Board of Directors Apr 29 2015
Endologix to Report First Quarter 2015 Financial Results on April 29, 2015 Apr 29 2015
ENDOLOGIX INC /DE/ Files SEC form 8-K, Results of Operations and Financial Condition Apr 29 2015
Endologix Reports 10% Revenue Growth for the First Quarter 2015 Apr 29 2015
Positive Nellix Clinical Data From the EVAS FORWARD Global Registry Presented at the 37th Annual... Apr 29 2015
Endologix Appoints Leslie Norwalk to Board of Directors Apr 29 2015
Q1 2015 Endologix Inc Earnings Release - After Market Close Apr 29 2015
Endologix to Report First Quarter 2015 Financial Results on April 29, 2015 Apr 13 2015
Endologix (ELGX) Enters Overbought Territory - Tale of the Tape Apr 01 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK